Theralase completes C$4.27mln public offering
Theralase Technologies Inc closed a public offering of units, raising C$4.2mln, the company said on Thursday
Company
Theralase Technologies Inc
CVE:TLT
Theralase Technologies Inc is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers.
80 stories · page 4 of 4
Theralase Technologies Inc to raise funds
The funds will be used to finance R&D activities by Theralase's Photo Dynamic Therapy division, commercialization activities by Theralase's Therapeutic Laser Technology division
Theralase tempers full-year sales expectations
The recently-released TLC-2000 is a big improvement on its predecessor and was expected to sell well
Theralase's PDT can increase GMB cancer survival by 925%
Theralase Technologies on Friday said its photodynamic therapy technology has been found to have the ability to increase survival by 925% in a very aggressive form of brain cancer, known as glioblastoma multiforme
Theralase receives Health Canada nod for TLC trial
Theralase Technologies Inc. said on Thursday Health Canada has granted investigational testing authorisation approval to use its patent-pending TLC-3200 photodynamic therapy laser system and TLC-3400 dosimetry fibre optic cage technology
Promising results for Theralase's technology in cancer test
It was only a small test on one rat, but the results were astonishing
Theralase expects bladder cancer trial green light by end of November
Pending Health Canada approval of the ITA, Theralase will immediately commence enrolment of patients into a Phase Ib clinical study in the treatment of non-muscle invasive bladder cancer.
Theralase seeks green light to start bladder cancer study
Theralase has been hard at work for a long time preparing for this application
Theralase receives US patent for TLD-1433 drug
Theralase Technologies said on Monday it has been granted a US patent for its lead anti-cancer drug, TLD-1433, by the United States Patent and Trademark Office
Theralase's laser technology: "It's light, Jim, but not as we know it"
Theralase's "bread & butter" business is the clinically proven therapeutic laser technology, being used to treat skin, muscle and nerve damage, while the photo dynamics compounds technology in development promises new hope for cancer suffer
Theralase set for phase Ib study for bladder cancer
The study will be conducted by the Department of Urology at the University Health Network (UHN)
Theralase to nearly double revenues as gears up for BRIC demand says Zacks
Theralase Technologies revenues are expected to nearly double this year, as the company focuses on demand from BRIC economies, according to an upbeat assessment from Zacks Investment Research
Theralase boosted by Canada revenues jump
Theralase Technologies shares rise after the company reports a 40% jump in total revenues for its fiscal 2015 and a near-doubling in Canada
Theralase Technologies Inc extends research partnership with UHN
The University Health Network (UHN) is one of the top-five cancer research institutes in the world.
Theralase Technologies' anti-cancer compound passes milestone
Proving stability in clinical trials means the drug can be used to treat patients in a clinical study
Theralase Technologies cancer treatment study published in medical journal
Photochemical & Photobiological Sciences is a publication of the Royal Society of Chemistry that focuses on photodynamic therapy.
US Risers & Fallers: PharmaCyte, Theralase, J.P. Morgan, MagneGas, Gold Resource, Best Buy
Best Buy shares sink after the electronics company cuts outlook following disappointing holiday sales.
Theralase debuts next generation therapeutic laser in US
The Canadian biotech maker will be performing product demonstrations of the TLC-2000 at a Las Vegas seminar.
Theralase Technologies gets clinical trial go-ahead
Health Canada has no objection to the proposed Phase Ib clinical study.
Theralase approved to sell next-gen laser in United States
The new TLC-2000 system, for temporary pain relief from knee disorders, can now immediately be marketed in the US,